RxDoctor Payments Data

David Baran, MD

Advanced Heart Failure and Transplant Cardiology · Weston, FLNPI 1871594150

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2019 at $50,973 and has fallen 83.2% since, to $8,583 in 2025.

$116,310in general payments, 2019–2025

Across 260 payments — averaging $447.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$24K
  • Pfizer$16K
  • Novartis$12K
  • Getinge USA Sales, LLC$11K
  • Abbott$8K
  • Alnylam Pharmaceuticals Inc.$7K
  • plus $39K from 30 others
$322,652in research payments, 2019–2025

Across 53 payments — averaging $6087.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$130K
  • Boehringer Ingelheim$73K
  • Astellas Pharma Global Development$58K
  • Transmedics, Inc.$47K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$7K
  • Xvivo Perfusion Inc.$3K
  • plus $4K from 2 others

What the payments were for

  • Consulting fees$25,85422%
  • Speaking & faculty fees$64,01255%
  • Travel & lodging$11,45910%
  • Food & beverage$14,97713%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,310 in reported general payments places this provider in the 85th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

See all advanced heart failure and transplant cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$134,180
Medicare patients
259
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan337$476,384
JardianceEmpagliflozin272$324,013
EliquisApixaban163$207,273
FarxigaDapagliflozin Propanediol48$61,324
XareltoRivaroxaban32$42,368
OzempicSemaglutide13$14,610
Repatha SureclickEvolocumab16$14,209
Tacrolimus39$8,973
Eplerenone52$5,830
Mycophenolate Mofetil27$5,012
VascepaIcosapent Ethyl14$4,307
Metoprolol Succinate227$4,276
Valganciclovir Hcl11$3,528
Torsemide103$2,714
Rosuvastatin Calcium131$2,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$11,928$476,384337 claims
PfizerEliquis$15,606$207,273163 claims
AstraZenecaFarxiga$382$61,32448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

Other advanced heart failure and transplant cardiology in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →